Proteomics International’s Managing Director Dr Richard Lipscombe was interviewed by Shares in Value, discussing the potential of the Promarker™ platform in allowing early disease detection and enabling precision medicine.
The lengthy discussion also focused on Proteomics International’s flagship prognostic test for diabetic kidney disease PromarkerD, the potential impact on patients with diabetes world-wide and the ongoing commercialisation activity.
You can watch the interview in full here.
